Myomo Inc (MYO) Stock Analysis

AI analysis of Myomo Inc (MYO)

Buy

Myomo Inc is a good buy right now due to its recent strong earnings report showing a 21% year-over-year revenue growth to $11.7 million and an impressive gross margin of 72.1%. The stock is currently priced at $1.20, significantly below the analyst's target price of $10.50, indicating substantial upside potential. Additionally, insider buying has surged by 1251.40% over the last month, suggesting strong confidence from those closest to the company. The main risk is the negative earnings per share (EPS) estimate of -0.08 for the upcoming quarter, indicating ongoing challenges in achieving profitability.

Analyst Ratings (1)

+383.19% upside

Buy

1 Buy

0 Hold

0 Sell

Current: 1.19

Low

4.00

Average

5.75

High

10.00

Ascendiant

Buy

$10

2026-08-27

Ascendiant

2026-08-27

Price Target

$10

Buy

Alliance Global

Buy

$3

2026-03-12

Alliance Global

2026-03-12

Price Target

$3

Buy

H.C. Wainwright

Buy

$5

2025-08-12

H.C. Wainwright

2025-08-12

Price Target

$5

Buy

Alliance Global Partners

Buy

—

2025-06-26

Alliance Global Partners

2025-06-26

Price Target

—

Buy

Craig-Hallum

Buy

$8

2025-06-23

Craig-Hallum

2025-06-23

Price Target

$8

Buy

See All Ratings

Valuation Metrics

The current forward P/E ratio for Myomo Inc (MYO) is 0.00, compared to its 5-year average forward P/E of -13.09.

Forward P/E

Fair

5Y Average P/E

-13.09

Current P/E

0.00

Overvalued

1.51

Undervalued

-27.69

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-12.51

Current EV/EBITDA

-7.82

Overvalued

9.77

Undervalued

-34.78

Forward P/S

Fair

5Y Average P/S

1.90

Current P/S

1.01

Overvalued

3.36

Undervalued

0.45

Alphio AI Price Scenarios for MYO

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MYO

$9.90

Scenario price

B

Base

Base · 50%MYO

$7.68

Scenario price

B

Bear

Bear · 25%MYO

$5.59

Scenario price

MYO FAQ — answered by Alphio AI

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. The Company develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Myomo Inc is a good buy right now due to its recent strong earnings report showing a 21% year-over-year revenue growth to $11.7 million and an impressive gross margin of 72.1%. The stock is currently priced at $1.20, significantly below the analyst's target price of $10.50, indicating substantial upside potential. Additionally, insider buying has surged by 1251.40% over the last month, suggesting strong confidence from those closest to the company. The main risk is the negative earnings per share (EPS) estimate of -0.08 for the upcoming quarter, indicating ongoing challenges in achieving profitability.

1 analysts cover MYO: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 5.75.